Skip to main content

Market Overview

Roche Reports Positive Evrysdi Data From Dose-Finding Part Of Spinal Muscular Atrophy Trial

Share:
  • Roche Holding AG (OTCMKTS: RHHBY) has reported positive data from the dose-finding Part 1 FIREFISH Phase 2/3 study of Evrysdi (risdiplam) in infants with symptomatic Type 1 spinal muscular atrophy (SMA).
  • Evrysdi helps in the survival of motor neuron 2 (SMN2) splicing modifier designed for treating SMA by boosting SMN protein production. The protein is vital to maintaining healthy motor neurons and movement.
  • According to the latest data from 21 infant participants, Evrysdi treatment at 12 months helped 90% of infants survive without needing permanent ventilation, and 33% sit without support for at least five seconds.
  • Furthermore, it raised the survival levels of SMN protein by a median 1.9-fold from baseline in the high-dose group at 12 months.
  • In the low- and high-dose cohorts, no infant lost the ability to swallow over 12 months, and 86% were able to feed orally, either exclusively or in combination with a feeding tube at 12 months.
  • Price Action: RHHBF is up 1.03% $344 in market trading hours on the last check Thursday.
 

Related Articles (RHHBY + RHHBF)

View Comments and Join the Discussion!

Posted-In: Phase 3 Trial Spinal Muscular AtrophyBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com